Health
bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization – Business Wire
Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary
MARCY LÉTOILE, France–(BUSINESS WIRE)–Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause…
-
Noosa News24 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
Noosa News13 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News23 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
General8 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline